(Total Views: 523)
Posted On: 10/15/2020 6:53:33 PM
Post# of 154867
The quote says clearly Dr. Hahn supports companies sharing data with the public. That's the first thing I want.
If safety and favorable risk/benefit are truly enough for an EUA, I would expect him to support an EUA for leronlimab. Or at least, as he promises in the quote, an explanation of his rationale for declining.
If safety and favorable risk/benefit are truly enough for an EUA, I would expect him to support an EUA for leronlimab. Or at least, as he promises in the quote, an explanation of his rationale for declining.
(4)
(0)
